May 21, 2019
ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) issued a statement in response to the Minnesota Senate’s passage of HF 400, which imposes annual fees on prescription opioid manufacturers and distributors.
“Imposing significant fees on the pharmaceutical supply chain represents a troubling trend in addressing the prescription drug abuse crisis that could ultimately limit access to legitimate medicines and increase costs for patients and healthcare providers.
“Throughout this legislative session in Minnesota, the Healthcare Distribution Alliance and many other organizations, including numerous patient advocacy groups, asserted that any reforms to address prescription drug abuse should focus on the addressing the root causes of the epidemic, which include overprescribing and the rapidly expanding use of illicit drugs like heroin and synthetic fentanyl.
“While we understand and appreciate the intent of the Minnesota Legislature to do something to address opioid abuse, we remain concerned that efforts to increase fees or discriminatory tariffs will only make it more difficult and more costly for patients and providers to access medicines.”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.